menu
    • menu
    [{"orgOrder":0,"company":"Agilent Technologies","sponsor":"Transcenta Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Nivolumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Agilent Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agilent Technologies \/ Agilent Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Agilent Technologies \/ Agilent Technologies"},{"orgOrder":0,"company":"Agilent Technologies","sponsor":"GI Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"GI-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agilent Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agilent Technologies \/ Agilent Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Agilent Technologies \/ Agilent Technologies"},{"orgOrder":0,"company":"Agilent Technologies","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agilent Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agilent Technologies \/ Agilent Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Agilent Technologies \/ Agilent Technologies"}]

    Find Clinical Drug Pipeline Developments & Deals by Agilent Technologies

    Menu

    Agilent Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Agilent Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Agilent Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Osemitamab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Transcenta Holding

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Transcenta Collaborates with Agilent To Develop Companion Diagnostic for Osemitamab

                            Details : The collaboration aims to develop a CLDN18.2 companion diagnostic for phase III TST001 (osemitamab) with nivolumab and chemotherapy in patients with advanced gastroesophageal adenocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            August 04, 2024

                            Lead Product(s) : Osemitamab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Transcenta Holding

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Agilent Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Agilent Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abemaciclib,Tamoxifen Citrate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Basilea Pharmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2-...

                            Details : Based on results, Verzenio may require dose modification. Monitor patients for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate. Advise patients of potential risk to a fetus and to use effective contraception.

                            Product Name : Verzenio

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 13, 2021

                            Lead Product(s) : Abemaciclib,Tamoxifen Citrate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Basilea Pharmaceutica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Agilent Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Agilent Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GI-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : GI Innovation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Agilent Announces MOU to Collaborate with GI Innovation for Biomarker Profiling in Phase 1/2 Study of Cancer I...

                            Details : The MOU establishes a framework in which the two companies will enter into a strategic partnership to explore potential genomic biomarkers of the tumor microenvironment in an early-phase trial of the investigational compound GI-101.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 11, 2020

                            Lead Product(s) : GI-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : GI Innovation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Agilent Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Agilent Technologies

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NK Cell Enriched Donor Lymphocytes,DUK-CPG-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Cristina Gasparetto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 25, 2015

                            Lead Product(s) : NK Cell Enriched Donor Lymphocytes,DUK-CPG-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Cristina Gasparetto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth